Pinter, Matthias; Weinmann, Arndt; Woerns, Marcus-Alexander et al.
Use of inhibitors of the renin-angiotensin system is associated with longer survival in patients with hepatocellular carcinomaUNITED EUROPEAN GASTROENTEROLOGY JOURNAL. Bd. 5. H. 7. 2017 S. 987-996
Kloeckner, Roman; Pitton, Michael B.; Dueber, Christoph et al.
Validation of Clinical Scoring Systems ART and ABCR after Transarterial Chemoembolization of Hepatocellular CarcinomaJOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY. Bd. 28. H. 1. 2017 S. 94-102
Maehringer-Kunz, Aline; Kloeckner, Roman; Pitton, Michael B. et al.
Validation of the Risk Prediction Models STATE-Score and START-Strategy to Guide TACE Treatment in Patients with Hepatocellular CarcinomaCARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY. Bd. 40. H. 7. 2017 S. 1017-1025
Ungerechts, Guy; Engeland, Christine E.; Buchholz, Christian J. et al.
Virotherapy Research in Germany: From Engineering to TranslationHUMAN GENE THERAPY. Bd. 28. H. 10. 2017 S. 800-819
Huber, Yvonne; Gehrke, Nadine; Biedenbach, Jana et al.
Voluntary distance running prevents TNF-mediated liver injury in mice through alterations of the intrahepatic immune milieuCELL DEATH & DISEASE. Bd. 8. 2017
Lutz, Manfred P.; Zalcberg, John R.; Glynne-Jones, Rob et al.
2nd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of rectal cancer (vol 63, pg 11, 2016)EUROPEAN JOURNAL OF CANCER. Bd. 68. 2016 S. 208-209
Bartalena, L.; Burch, H. B.; Burman, K. D. et al.
A 2013 European survey of clinical practice patterns in the management of Graves' diseaseCLINICAL ENDOCRINOLOGY. Bd. 84. H. 1. 2016 S. 115-120
Zhu, A. X.; Galle, P. R.; Kudo, M. et al.
A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2)ANNALS OF ONCOLOGY. Bd. 27. 2016
Zhu, Andrew X.; Galle, Peter R.; Kudo, Masatoshi et al.
A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2).JOURNAL OF CLINICAL ONCOLOGY. Bd. 34. H. 4. 2016
Foerster, Friedrich; Hess, Moritz; Gerhold-Ay, Aslihan et al.
An in silico analysis of the immunome of hepatocellular carcinoma reveals a prognostic immune gene signatureHEPATOLOGY. Bd. 63. H. 1 SUPP. 2016 S. 91A-91A